this Thank thank revised made you, call. and good progress Lisa, you strategy call QX our the for during discussed during QX joining afternoon. We our all executing
reminder, and promising of Sight number efficient related indicated a programs; number technologies on X, provide focus execution development X, use and of Orion powerful to one, experience patients. number objectives; that to I As that the clinical of R&D a the would commercial X the Argus activities; and richer more Second advancement our capital major
his Chairman relative like all During Board, our the I for provide updates of first But call, I continued objectives. Gregg thank of to support the would Williams, would to company.
XX to continued invested a blind our from financial has innovative position company the call. strong will future in via he a XXXX, John During almost private as talk in more million develop shared reflects commitment later well vision hope offer to Gregg’s that exciting belief with in company's cause technologies the Orion. the as individuals any financial placements. about
at implanted Ronald of conducting College Orion Houston. Medical Medicine an the part feasibility to with Baylor Reagan Today, on are and we UCLA Orion there where turn Let's of as which study early are individuals X our update and with program. Center we're in
We are subject to a at Baylor. be actively recruiting implanted Xth
without rehab and rehab to do sessions have entails home to subjects customized parameters vision for important glasses. cleared captured The subjects able is using the The potentially with subjects them of for vision full safe. home goals. milestone assist off overall identified it and camera be curb, Orion from reflects rehab of specific Observations in by things in the which signs, light encouraged to a subject’s the reaching belief subjects use artificial in All four we look and an the dark are locating forward the on that more they are responding effective training. been it that we performance critical rehabilitation laundry. the process updates more of implanted through Each have regular artificial begun including Orion from the providing have drop continue vision have importantly time of for because vision and artificial indicate sorting do stimulation front Four the All them, that are will to been their to training Orion. people a identifying in future. system X locating embedded continue which creates of subjects we use well the in video by couldn't real cleared basis
Although for study are objective to endpoints subjects. function anticipated the order life objective our and In finalize improvements. concerning an that visual measure data require the from sessions with we from additional of the anecdotal exciting, trial the FDA feasibility agreement endpoints, rehab need Orion more performance and observations Orion will quality
the are of We performance early year end targeting to necessary or this data. next gather the year
are the trial. clear, note we to performance pivotal FDA to performance and then move the with of XXXX. expectation could and in data sufficiently is XXXX quantify decided with if six trial our the that move pivotal without significant the half additional in to work. finalize first clinical a enrolled first like safety changes goal to a to with patients with system, we continuing forward to Orion be the can't be pathway the I'd sharing patients additional this But feasibility make to or for investors regulatory feasibility we would the before good, if of Assuming to
pleased I'm Health our or awarded we to NIH. million have National there grant from SAEs delighted been We additional call. Institutes of say or been also one were events $X.X during SAE the have to the last Finally, significant no adverse discussed since
over X for intent years. very Orion the years I'm over to past Orion’s of with X.X progress million their development. tremendous fund team's With clinical support the pleased X
from We coming vision Argus months. to implants cortical the quarter, stimulation in to business. in implanted we I'd XXXX. look confidence X.X now database. creating completed in implants million up coming X providing continues artificial of from resulting of had the XX North patients patient of the X more from and the America, the prior quarter XX during quarter potential implants to we and the U.S. I our direct year-over-year, QX were during of like turn Our updates significantly in revenue the X sequentially via our with Argus up to forward grow In
Italy, As discussed our support drive core restructuring executing we strategy allow America North to will America, of on direct is to in a many Germany, the eventually North England. in markets order centers business of times, are focus on Outside our excellence of in our key adoption. which to us and focus France,
most being intent our in which and support beginning We savings we million totaling in accounts our deliberate focus selective promising concerning confidence indirect we an XXXX. annual we post-surgery. on X By operating expense reimbursement high and markets regulatory geographies have that patients and more to to funding, anticipate infrastructure approval, also of support,
please to Importantly, will we be that support assured anywhere patients existing continue world. in the
really such the setting CMS to pleased average consider few hard for change in finalized to should outpatient the over for the by Argus. reimbursement data the hospital rate I year of and $XXX,XXX now the changes On reimbursement rate the Medicare rate also methodology were date the initiatives. applaud successfully to payment to Argus. U.S. temper of highest access this our a years will related fluctuations This for multiple year, reimbursement historical advance the of the future rate. devices reimbursement announce appreciate versus market we reimbursement with one past year setting as front, team work I represents Argus rate U.S. procedural low CMS and the volume recently for to cost. II host just years
the decision in receive by we and continues early Turning national reimbursement US, move we to Forfait confident next France year. remain outside that a Innovation process will forward
the positive We are England under Finally, to reimbursement in seen similar key program or senior II Commissioning XXXX. preparing sufficiently regard are of in this begin Argus leadership in were optimistic NHS first filings and with reimbursement testing quarter to in in contact issues the later CTE regulatory first with issues occur we testing and the implants few Xs, for on believe movement over to that a XX We Evaluation been we will the projected our With identified developments, during England, Argus clinical past close final innovation we team gen England. stakeholders and this next II have other CTE program Argus early based XXXX. recent Through relative the addressed externals, have half days. QX
the a also he Xs externals for base trial. as As in pivotal Orion the Argus will externals serve reminder,
say Before a like our to closing, few projects. research concerning I'd words
are Argus these well such in in research and distance technologies and as thermal outlined eye-tracking, pursuing last benefit recognition, our users, filtering, call, as Orion as ultimately. As users object imaging. We believe we facial will areas
clinical moving prioritizing be we'll the and programs technology testing all XXXX. on technologies of most progress good into or here goal with making are in We the promising them
team. like Finally to I'd the welcome Ryan Pat to
Second Pat develop and Chief joined of to teams. our previously ability the As years Sight with brings skills proven He experience great along the medical build to announced, leadership company device many Operating as and Officer.
to realign patients to company we of results. actions with greatest the With that, the Pat the to review the financial call a now return significantly also position, like John? John of to quarter benefit additions third combined while Ryan, turn the leadership to These this larger business possible strengthened team providing John recent I’d Blake to With shareholders. the and to the have number provide believe I our year. best our over changes
